Header Logo

Saad Usmani

Concepts (509)

Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.


Name Number of Publications Most Recent Publication Publications by All Authors Concept Score Why?
Multiple Myeloma
249
2025
348
60.130
Why?
Antineoplastic Combined Chemotherapy Protocols
110
2025
446
19.480
Why?
Antibodies, Monoclonal
79
2025
868
14.540
Why?
Dexamethasone
70
2025
204
9.720
Why?
Antineoplastic Agents
36
2024
662
9.370
Why?
Hematopoietic Stem Cell Transplantation
38
2024
350
6.530
Why?
Immunotherapy, Adoptive
29
2025
96
5.760
Why?
Neoplasm Recurrence, Local
45
2025
337
5.370
Why?
Antineoplastic Agents, Immunological
15
2025
46
5.310
Why?
Antibodies, Bispecific
14
2025
31
4.850
Why?
B-Cell Maturation Antigen
18
2025
20
4.620
Why?
Bortezomib
32
2025
56
4.300
Why?
Neoplasm, Residual
19
2025
42
4.160
Why?
Humans
277
2025
63051
3.610
Why?
Thalidomide
21
2024
34
3.540
Why?
Antibodies, Monoclonal, Humanized
16
2025
233
3.070
Why?
Aged
114
2025
14268
2.850
Why?
Transplantation, Autologous
32
2024
127
2.600
Why?
Treatment Outcome
58
2025
5597
2.410
Why?
Middle Aged
103
2025
17605
2.260
Why?
Recurrence
28
2025
635
2.240
Why?
Hematologic Neoplasms
5
2025
49
2.230
Why?
Male
120
2025
29773
2.210
Why?
Female
121
2025
32755
2.090
Why?
Drug Resistance, Neoplasm
25
2024
195
2.060
Why?
Drug-Related Side Effects and Adverse Reactions
4
2023
143
2.020
Why?
Oligopeptides
15
2025
133
1.990
Why?
Aged, 80 and over
50
2025
5410
1.900
Why?
Adult
77
2025
16658
1.840
Why?
Biomarkers, Tumor
16
2025
504
1.830
Why?
Plasma Cells
8
2022
52
1.570
Why?
Prognosis
34
2025
1730
1.570
Why?
Neoplasms, Second Primary
5
2023
47
1.540
Why?
Injections, Subcutaneous
10
2022
70
1.480
Why?
Chromosome Aberrations
8
2025
68
1.400
Why?
T-Lymphocytes
8
2024
1003
1.370
Why?
Melphalan
9
2024
23
1.360
Why?
ADP-ribosyl Cyclase 1
6
2023
28
1.340
Why?
Clinical Trials as Topic
10
2023
453
1.310
Why?
Salvage Therapy
9
2023
72
1.290
Why?
Administration, Intravenous
8
2022
66
1.260
Why?
Quality of Life
9
2025
1220
1.230
Why?
Immunologic Factors
7
2022
104
1.170
Why?
Survival Rate
18
2025
845
1.100
Why?
Flow Cytometry
5
2022
669
1.090
Why?
Practice Guidelines as Topic
7
2024
726
1.070
Why?
Cell- and Tissue-Based Therapy
6
2023
39
1.060
Why?
Retrospective Studies
32
2025
6558
1.060
Why?
Myeloma Proteins
7
2021
7
1.030
Why?
Immunoglobulin Light Chains
4
2021
16
0.990
Why?
Waldenstrom Macroglobulinemia
3
2023
8
0.980
Why?
HSP90 Heat-Shock Proteins
3
2011
65
0.960
Why?
Physicians
4
2023
464
0.950
Why?
Positron-Emission Tomography
4
2015
208
0.930
Why?
Chromosomes, Human, Pair 1
4
2025
23
0.920
Why?
Membrane Glycoproteins
5
2020
668
0.890
Why?
Patient Reported Outcome Measures
5
2025
146
0.830
Why?
Smoldering Multiple Myeloma
5
2024
5
0.810
Why?
Maintenance Chemotherapy
4
2021
14
0.790
Why?
CD3 Complex
1
2022
65
0.770
Why?
Immunotherapy
5
2024
251
0.770
Why?
Injection Site Reaction
2
2021
3
0.760
Why?
Disease-Free Survival
15
2022
242
0.760
Why?
Health Status Disparities
1
2023
142
0.750
Why?
Disease Progression
15
2024
1158
0.720
Why?
Sulfides
2
2020
22
0.710
Why?
Acetates
2
2020
32
0.710
Why?
Quinolines
2
2020
44
0.710
Why?
Cyclopropanes
2
2020
49
0.700
Why?
Proteasome Inhibitors
10
2023
31
0.700
Why?
Immunoconjugates
2
2024
90
0.690
Why?
Spectrometry, Mass, Electrospray Ionization
1
2021
93
0.690
Why?
Transplantation Conditioning
5
2019
102
0.690
Why?
Amyloidosis
3
2016
64
0.690
Why?
Cytochrome P-450 CYP1A2 Inducers
1
2020
1
0.690
Why?
Risk Assessment
7
2025
2048
0.680
Why?
Models, Statistical
1
2022
307
0.670
Why?
Thromboembolism
1
2020
73
0.670
Why?
Neoplasm Staging
9
2025
489
0.660
Why?
Drug Administration Schedule
8
2021
299
0.650
Why?
Immunophenotyping
2
2018
193
0.630
Why?
Practice Patterns, Physicians'
2
2024
708
0.620
Why?
Consensus
8
2025
226
0.620
Why?
Karnofsky Performance Status
1
2019
12
0.620
Why?
Skin Neoplasms
2
2016
412
0.620
Why?
Induction Chemotherapy
7
2023
41
0.620
Why?
Translocation, Genetic
6
2025
71
0.610
Why?
Follow-Up Studies
16
2025
2446
0.610
Why?
Immunomodulation
1
2018
30
0.610
Why?
Dental Prophylaxis
1
2018
1
0.580
Why?
Gene Expression Profiling
8
2025
767
0.580
Why?
Kaplan-Meier Estimate
8
2021
419
0.570
Why?
Clinical Trials, Phase III as Topic
6
2025
42
0.570
Why?
Fluorodeoxyglucose F18
3
2017
95
0.550
Why?
Signaling Lymphocytic Activation Molecule Family
1
2017
6
0.550
Why?
Genomics
6
2025
368
0.550
Why?
Central Nervous System Neoplasms
2
2016
39
0.540
Why?
Survival Analysis
7
2020
579
0.540
Why?
Lymphoma, B-Cell
3
2025
61
0.540
Why?
Catheterization, Central Venous
1
2018
86
0.540
Why?
Dose-Response Relationship, Drug
6
2025
863
0.540
Why?
Bacteremia
1
2018
94
0.530
Why?
Cancer Survivors
1
2018
113
0.530
Why?
Infusions, Intravenous
4
2021
174
0.520
Why?
Blood Transfusion
1
2017
161
0.520
Why?
Ambulatory Care
1
2019
310
0.520
Why?
Antineoplastic Agents, Alkylating
1
2016
34
0.520
Why?
Cell Proliferation
2
2020
978
0.520
Why?
Incidence
7
2024
1371
0.510
Why?
Oligonucleotide Array Sequence Analysis
1
2017
296
0.510
Why?
United States
12
2023
7949
0.510
Why?
Disease Management
6
2021
234
0.510
Why?
Myeloproliferative Disorders
1
2016
15
0.510
Why?
Health Status
1
2019
432
0.510
Why?
Skin Diseases, Infectious
1
2016
12
0.500
Why?
Bone Marrow
7
2023
181
0.500
Why?
Plasmacytoma
3
2022
9
0.500
Why?
Molecular Targeted Therapy
4
2020
129
0.500
Why?
Boron Compounds
3
2024
20
0.460
Why?
Prospective Studies
13
2025
3257
0.450
Why?
Glycine
3
2024
49
0.450
Why?
Gene Expression Regulation, Neoplastic
7
2025
521
0.440
Why?
Biomarkers
7
2022
1388
0.440
Why?
Tumor Microenvironment
5
2023
152
0.440
Why?
Combined Modality Therapy
7
2021
370
0.440
Why?
Remission Induction
6
2025
147
0.440
Why?
Proportional Hazards Models
8
2023
943
0.440
Why?
Hepatitis C
1
2016
151
0.430
Why?
Thrombocytopenia
2
2025
54
0.430
Why?
Killer Cells, Natural
3
2020
217
0.430
Why?
Neoplasms
2
2018
1348
0.420
Why?
Serum Amyloid A Protein
1
2013
7
0.420
Why?
Young Adult
12
2025
4646
0.410
Why?
Leukemia
1
2013
62
0.400
Why?
Receptors, G-Protein-Coupled
2
2024
126
0.400
Why?
Standard of Care
2
2023
27
0.390
Why?
Clinical Trials, Phase II as Topic
4
2023
25
0.390
Why?
Neoplasms, Plasma Cell
2
2023
3
0.380
Why?
Soft Tissue Neoplasms
1
2012
31
0.380
Why?
Myelodysplastic Syndromes
1
2013
87
0.380
Why?
Hemophilia A
1
2011
57
0.370
Why?
Immunoglobulins, Intravenous
1
2011
35
0.370
Why?
Antibodies, Monoclonal, Murine-Derived
1
2011
58
0.370
Why?
Bone Neoplasms
1
2013
125
0.370
Why?
Frailty
2
2025
130
0.370
Why?
In Situ Hybridization, Fluorescence
5
2020
168
0.370
Why?
Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization
2
2021
84
0.360
Why?
Clinical Decision-Making
3
2025
160
0.360
Why?
Risk Factors
10
2024
5297
0.350
Why?
Cost-Benefit Analysis
2
2024
309
0.350
Why?
Benzodioxoles
1
2010
13
0.350
Why?
Purines
1
2010
42
0.350
Why?
Clinical Trials, Phase I as Topic
3
2023
15
0.340
Why?
Monoclonal Gammopathy of Undetermined Significance
3
2024
33
0.340
Why?
Lymphoma, T-Cell
2
2025
24
0.340
Why?
Cytogenetic Analysis
5
2022
25
0.340
Why?
Immunoglobulin Light-chain Amyloidosis
2
2021
6
0.340
Why?
Hematopoietic Stem Cell Mobilization
3
2022
15
0.340
Why?
Positron Emission Tomography Computed Tomography
3
2020
51
0.330
Why?
Magnetic Resonance Imaging
7
2018
2144
0.330
Why?
DNA Copy Number Variations
3
2024
72
0.330
Why?
Adolescent
9
2025
6189
0.320
Why?
Protein-Tyrosine Kinases
2
2025
125
0.320
Why?
Europe
2
2020
194
0.320
Why?
Stem Cell Transplantation
3
2023
79
0.320
Why?
Benzoquinones
1
2009
14
0.320
Why?
Healthcare Disparities
2
2023
349
0.320
Why?
Liver Neoplasms
1
2012
297
0.310
Why?
Lactams, Macrocyclic
1
2009
25
0.310
Why?
Randomized Controlled Trials as Topic
7
2024
726
0.300
Why?
Boronic Acids
3
2013
28
0.290
Why?
Pyrazines
3
2013
34
0.290
Why?
Neutropenia
3
2023
67
0.290
Why?
Chromosome Deletion
2
2020
42
0.280
Why?
Bone Marrow Cells
4
2022
238
0.280
Why?
T-Lymphocytes, Regulatory
2
2020
212
0.270
Why?
Databases, Factual
4
2020
852
0.270
Why?
Myeloablative Agonists
3
2015
13
0.260
Why?
Diarrhea
2
2024
75
0.250
Why?
Adrenal Cortex Hormones
2
2024
173
0.240
Why?
Cross-Sectional Studies
2
2024
2556
0.240
Why?
Antigens, CD19
1
2025
22
0.240
Why?
Immunity, Humoral
1
2025
40
0.240
Why?
Chemoradiotherapy
1
2025
65
0.240
Why?
Mutagenesis
1
2025
133
0.230
Why?
Receptors, Antigen, T-Cell
2
2024
287
0.230
Why?
Surveys and Questionnaires
2
2024
2642
0.220
Why?
Chromatography, Liquid
2
2021
131
0.220
Why?
Whole Genome Sequencing
4
2025
79
0.220
Why?
Mutation
4
2025
2588
0.220
Why?
Neoplasm Proteins
2
2018
283
0.220
Why?
Proteasome Endopeptidase Complex
2
2016
126
0.210
Why?
Models, Theoretical
1
2025
270
0.210
Why?
Rituximab
2
2015
87
0.210
Why?
CD47 Antigen
1
2023
3
0.210
Why?
Meta-Analysis as Topic
1
2023
78
0.200
Why?
Heterocyclic Compounds
1
2022
12
0.200
Why?
Gene Deletion
2
2024
308
0.200
Why?
Spain
2
2020
33
0.200
Why?
Gene Dosage
2
2021
65
0.200
Why?
Tumor Suppressor Protein p53
1
2025
303
0.200
Why?
Sex Factors
2
2023
972
0.200
Why?
Graft vs Host Disease
1
2023
111
0.190
Why?
Cell Cycle Proteins
1
2025
393
0.190
Why?
Canada
2
2020
153
0.190
Why?
Animals
10
2024
20591
0.190
Why?
Workflow
1
2022
68
0.190
Why?
Tomography, X-Ray Computed
3
2018
1589
0.190
Why?
Biological Therapy
1
2022
16
0.190
Why?
Artificial Intelligence
1
2024
163
0.190
Why?
Leukemia, Plasma Cell
1
2021
2
0.190
Why?
Software
1
2025
383
0.190
Why?
Cell Line, Tumor
5
2016
1457
0.180
Why?
CD8-Positive T-Lymphocytes
2
2024
674
0.180
Why?
Electrocardiography
1
2024
553
0.180
Why?
Nutritional Status
1
2022
98
0.180
Why?
Drug Administration Routes
1
2021
21
0.180
Why?
Time Factors
5
2020
3744
0.180
Why?
Population Surveillance
2
2020
204
0.180
Why?
Retreatment
2
2019
47
0.180
Why?
Immunoglobulin A
1
2021
97
0.170
Why?
Genetic Loci
1
2021
118
0.170
Why?
Administration, Cutaneous
1
2020
31
0.170
Why?
Patient Dropouts
1
2020
49
0.170
Why?
Leukemia, Myeloid, Acute
1
2023
191
0.170
Why?
Denmark
1
2020
17
0.170
Why?
Netherlands
1
2020
24
0.170
Why?
Medical Oncology
1
2021
65
0.170
Why?
Infusion Pumps
1
2020
7
0.170
Why?
Patient Satisfaction
2
2021
432
0.170
Why?
Sweden
1
2020
56
0.170
Why?
Disease Susceptibility
1
2020
166
0.170
Why?
Influenza, Human
1
2022
207
0.170
Why?
Hemoglobins
2
2018
135
0.160
Why?
Mass Spectrometry
1
2021
304
0.160
Why?
Drug Compounding
1
2020
76
0.160
Why?
Diagnostic Imaging
2
2020
263
0.160
Why?
Prednisone
1
2019
86
0.160
Why?
Thrombopoietin
1
2019
11
0.160
Why?
Immunoglobulin G
1
2021
466
0.160
Why?
Apoptosis
3
2023
1071
0.160
Why?
Paraproteinemias
1
2019
16
0.160
Why?
Cancer Care Facilities
1
2019
17
0.160
Why?
Diphenhydramine
1
2019
9
0.160
Why?
Premedication
1
2019
18
0.160
Why?
Outpatient Clinics, Hospital
1
2019
39
0.160
Why?
Transplantation, Haploidentical
1
2018
4
0.160
Why?
Venous Thromboembolism
1
2020
148
0.150
Why?
Cystitis
1
2018
10
0.150
Why?
Receptors, KIR
1
2018
4
0.150
Why?
Stem Cells
1
2021
257
0.150
Why?
Ibuprofen
1
2018
18
0.150
Why?
Myeloid-Derived Suppressor Cells
1
2018
7
0.150
Why?
B-Lymphocytes, Regulatory
1
2018
5
0.150
Why?
Multimodal Imaging
1
2019
67
0.150
Why?
Thoracic Vertebrae
1
2018
33
0.150
Why?
Diabetes Mellitus
1
2024
537
0.150
Why?
Cell Count
1
2018
129
0.150
Why?
Antibody-Dependent Cell Cytotoxicity
1
2018
26
0.150
Why?
Cytogenetics
2
2016
9
0.150
Why?
Models, Biological
2
2020
1182
0.150
Why?
Patient Safety
1
2021
241
0.150
Why?
Risk
5
2021
590
0.150
Why?
Back Pain
1
2018
50
0.150
Why?
Acetaminophen
1
2019
59
0.150
Why?
Precancerous Conditions
2
2016
69
0.150
Why?
Immunoglobulin Fc Fragments
1
2018
46
0.150
Why?
Periodontal Index
1
2018
4
0.150
Why?
Drugs, Investigational
1
2018
12
0.150
Why?
Pandemics
1
2023
661
0.140
Why?
Receptors, IgG
1
2018
41
0.140
Why?
Bone and Bones
2
2016
142
0.140
Why?
Antibiotic Prophylaxis
1
2018
55
0.140
Why?
Catheter-Related Infections
1
2018
42
0.140
Why?
Neoadjuvant Therapy
1
2018
82
0.140
Why?
Glucocorticoids
1
2019
188
0.140
Why?
Comorbidity
1
2020
1112
0.140
Why?
Phagocytosis
1
2018
264
0.130
Why?
Lumbar Vertebrae
1
2018
154
0.130
Why?
Chronic Disease
1
2020
751
0.130
Why?
Hemorrhage
1
2018
267
0.130
Why?
B-Lymphocytes
1
2020
569
0.130
Why?
Feasibility Studies
1
2019
562
0.130
Why?
Odds Ratio
1
2018
768
0.130
Why?
Gene Expression
1
2020
837
0.130
Why?
Zonula Occludens-1 Protein
1
2016
7
0.130
Why?
Leukemia, Lymphocytic, Chronic, B-Cell
1
2016
46
0.130
Why?
Janus Kinase 1
1
2016
11
0.130
Why?
Pneumonia
1
2019
288
0.130
Why?
Schnitzler Syndrome
1
2016
1
0.130
Why?
Scleromyxedema
1
2016
1
0.130
Why?
POEMS Syndrome
1
2016
2
0.130
Why?
Cryoglobulinemia
1
2016
3
0.130
Why?
Xanthomatosis
1
2016
8
0.130
Why?
Cohort Studies
3
2019
2763
0.130
Why?
Osteoclasts
2
2013
48
0.130
Why?
Radiopharmaceuticals
2
2017
186
0.130
Why?
Genetic Predisposition to Disease
1
2020
714
0.130
Why?
Phenotype
1
2020
1195
0.130
Why?
STAT3 Transcription Factor
1
2016
70
0.120
Why?
Biomarkers, Pharmacological
2
2012
6
0.120
Why?
ErbB Receptors
1
2016
114
0.120
Why?
Lymphoma, Follicular
1
2015
16
0.120
Why?
Bone Marrow Transplantation
1
2015
139
0.120
Why?
Immunoglobulin Heavy Chains
2
2025
46
0.120
Why?
Bone Remodeling
1
2015
25
0.120
Why?
Mice
5
2024
10809
0.120
Why?
Costs and Cost Analysis
1
2015
102
0.110
Why?
Genetic Markers
1
2015
127
0.110
Why?
Medicare
1
2019
612
0.110
Why?
Histone Deacetylase Inhibitors
1
2014
36
0.110
Why?
Chromosomes, Human, Pair 17
1
2014
24
0.110
Why?
Antigens, CD34
1
2013
56
0.110
Why?
Unfolded Protein Response
2
2013
56
0.110
Why?
Cerebrospinal Fluid
1
2013
24
0.110
Why?
Renal Insufficiency
1
2014
282
0.110
Why?
Administration, Metronomic
1
2013
2
0.110
Why?
Cell Separation
1
2013
147
0.110
Why?
Radiography
2
2012
535
0.110
Why?
Transplantation, Homologous
3
2022
244
0.110
Why?
Castleman Disease
1
2013
4
0.110
Why?
Nicotinamide Phosphoribosyltransferase
1
2013
5
0.100
Why?
Angiogenesis Inhibitors
1
2014
77
0.100
Why?
beta Catenin
1
2013
94
0.100
Why?
Osteolysis
1
2013
17
0.100
Why?
Bone Diseases
1
2013
22
0.100
Why?
Piperidines
3
2020
62
0.100
Why?
Signal Transduction
5
2016
3023
0.100
Why?
Cell Cycle
2
2013
393
0.100
Why?
Mice, SCID
4
2016
519
0.100
Why?
Myelolipoma
1
2012
1
0.100
Why?
Antiretroviral Therapy, Highly Active
1
2013
95
0.100
Why?
Receptors, Glucocorticoid
1
2012
26
0.100
Why?
Genome, Human
2
2025
239
0.100
Why?
Longitudinal Studies
3
2024
1243
0.100
Why?
Hemarthrosis
1
2011
3
0.100
Why?
Severity of Illness Index
2
2020
1541
0.090
Why?
Factor VIII
1
2011
32
0.090
Why?
Granulocyte Colony-Stimulating Factor
2
2022
41
0.090
Why?
Blood Coagulation Factors
1
2011
16
0.090
Why?
Pericardial Effusion
1
2011
21
0.090
Why?
Hydrazines
2
2022
10
0.090
Why?
Vaccination
2
2025
356
0.090
Why?
Epigenesis, Genetic
1
2015
384
0.090
Why?
Triazoles
2
2022
56
0.090
Why?
Acute Disease
1
2013
669
0.090
Why?
Cell Movement
1
2013
447
0.090
Why?
Autoantibodies
1
2011
182
0.090
Why?
Drug Evaluation, Preclinical
1
2011
97
0.090
Why?
Body Weight
2
2023
376
0.090
Why?
Heart Failure
1
2018
904
0.090
Why?
G1 Phase
1
2010
56
0.090
Why?
Multivariate Analysis
1
2013
933
0.090
Why?
S Phase
1
2010
78
0.080
Why?
Drug Therapy, Combination
1
2011
462
0.080
Why?
Multicenter Studies as Topic
2
2021
137
0.080
Why?
Pain
2
2023
403
0.080
Why?
Diet
2
2024
522
0.080
Why?
Cyclophosphamide
2
2021
79
0.080
Why?
Fatigue
2
2022
112
0.080
Why?
Metabolic Clearance Rate
2
2020
49
0.080
Why?
International Agencies
2
2019
7
0.080
Why?
Drug Screening Assays, Antitumor
1
2009
82
0.080
Why?
Cell Differentiation
4
2018
1350
0.080
Why?
Adenine
2
2020
50
0.080
Why?
Cytokines
1
2013
931
0.080
Why?
Pyrazoles
2
2020
78
0.070
Why?
Nausea
1
2009
112
0.070
Why?
Pyrimidines
2
2020
135
0.070
Why?
Vomiting
1
2009
138
0.070
Why?
CD4-Positive T-Lymphocytes
2
2025
641
0.070
Why?
Algorithms
2
2025
998
0.070
Why?
Body Mass Index
2
2023
860
0.070
Why?
Doxorubicin
2
2021
98
0.070
Why?
Cisplatin
2
2021
139
0.070
Why?
Thymus Hyperplasia
1
2006
2
0.070
Why?
Chemotherapy, Adjuvant
1
2006
85
0.060
Why?
HIV Infections
1
2013
965
0.060
Why?
Trisomy
1
2025
21
0.060
Why?
Brain
1
2013
1552
0.060
Why?
Fatal Outcome
1
2025
124
0.060
Why?
Lentivirus
1
2025
66
0.060
Why?
Genes, Tumor Suppressor
1
2024
72
0.060
Why?
Sweetening Agents
1
2024
21
0.050
Why?
Protein Interaction Maps
1
2023
35
0.050
Why?
Cell Transformation, Neoplastic
1
2025
206
0.050
Why?
Ki-67 Antigen
1
2023
37
0.050
Why?
Diet, Vegetarian
1
2022
3
0.050
Why?
Nutrition Surveys
1
2024
142
0.050
Why?
Germinal Center
1
2023
40
0.050
Why?
Proteinuria
1
2023
41
0.050
Why?
Butyrates
1
2022
16
0.050
Why?
Immunoglobulins
1
2023
77
0.050
Why?
Myeloid Differentiation Factor 88
1
2023
203
0.050
Why?
Homeodomain Proteins
1
2024
267
0.050
Why?
Drug Combinations
1
2022
165
0.050
Why?
Single-Chain Antibodies
1
2021
7
0.050
Why?
Diterpenes
1
2021
21
0.050
Why?
Filgrastim
1
2021
8
0.050
Why?
Etoposide
1
2021
34
0.050
Why?
RNA Interference
2
2016
618
0.040
Why?
Taiwan
1
2021
11
0.040
Why?
Neurotoxicity Syndromes
1
2021
21
0.040
Why?
Japan
1
2021
59
0.040
Why?
Immunoglobulin kappa-Chains
1
2020
9
0.040
Why?
Immunoglobulin lambda-Chains
1
2020
10
0.040
Why?
Immunohistochemistry
1
2023
891
0.040
Why?
Up-Regulation
2
2013
375
0.040
Why?
Lymphoproliferative Disorders
1
2021
39
0.040
Why?
Liver Function Tests
1
2020
39
0.040
Why?
Cost Savings
1
2021
53
0.040
Why?
Lymphoma, Non-Hodgkin
1
2021
53
0.040
Why?
Case-Control Studies
1
2024
1113
0.040
Why?
Neoplastic Cells, Circulating
1
2020
15
0.040
Why?
Benchmarking
1
2021
134
0.040
Why?
Injections, Intravenous
1
2020
156
0.040
Why?
Molecular Diagnostic Techniques
1
2020
32
0.040
Why?
Antibodies, Neutralizing
1
2022
208
0.040
Why?
Kidney
1
2023
444
0.040
Why?
Chromosomes, Human
1
2020
54
0.040
Why?
Republic of Korea
1
2021
162
0.040
Why?
ROC Curve
1
2020
280
0.040
Why?
Reference Values
1
2020
337
0.040
Why?
Prevalence
1
2024
1363
0.040
Why?
Stevens-Johnson Syndrome
1
2019
8
0.040
Why?
Delivery of Health Care
1
2023
431
0.040
Why?
Jehovah's Witnesses
1
2019
18
0.040
Why?
Pain Measurement
1
2020
340
0.040
Why?
High-Throughput Nucleotide Sequencing
1
2021
312
0.040
Why?
Maximum Tolerated Dose
1
2019
40
0.040
Why?
Patient Acceptance of Health Care
1
2023
475
0.040
Why?
Global Health
1
2020
181
0.040
Why?
Health Care Costs
1
2021
206
0.040
Why?
Basophils
1
2018
14
0.040
Why?
Granzymes
1
2018
21
0.040
Why?
Antigens, Differentiation, T-Lymphocyte
1
2018
109
0.040
Why?
Drug Approval
1
2018
26
0.040
Why?
Myocarditis
1
2019
66
0.040
Why?
Autografts
1
2017
9
0.040
Why?
Hematology
1
2017
12
0.040
Why?
Allografts
1
2017
46
0.040
Why?
Education
1
2017
69
0.030
Why?
Breast Neoplasms
1
2006
1194
0.030
Why?
Polymorphism, Genetic
1
2018
192
0.030
Why?
RNA, Small Interfering
2
2013
908
0.030
Why?
Peripheral Nervous System Diseases
1
2016
28
0.030
Why?
Erlotinib Hydrochloride
1
2016
20
0.030
Why?
Atrial Fibrillation
1
2024
836
0.030
Why?
Radiotherapy
1
2016
64
0.030
Why?
Research Design
1
2019
571
0.030
Why?
Genetic Testing
1
2016
131
0.030
Why?
Cysteine Endopeptidases
1
2016
94
0.030
Why?
Reproducibility of Results
1
2020
1639
0.030
Why?
Child
1
2025
4479
0.030
Why?
Xenograft Model Antitumor Assays
1
2016
188
0.030
Why?
Neoplasm Grading
1
2015
87
0.030
Why?
Societies, Medical
1
2017
368
0.030
Why?
Hospitalization
1
2022
1342
0.030
Why?
Blotting, Western
1
2016
607
0.030
Why?
Reverse Transcriptase Polymerase Chain Reaction
1
2016
545
0.030
Why?
Survivors
1
2015
169
0.030
Why?
Karyotype
1
2014
18
0.030
Why?
Interspersed Repetitive Sequences
1
2014
13
0.030
Why?
Low Density Lipoprotein Receptor-Related Protein-1
1
2013
2
0.030
Why?
Low Density Lipoprotein Receptor-Related Protein-6
1
2013
3
0.030
Why?
Syndecan-1
1
2013
9
0.030
Why?
Regulatory Factor X Transcription Factors
1
2013
15
0.030
Why?
X-Box Binding Protein 1
1
2013
13
0.030
Why?
Receptors, LDL
1
2013
34
0.030
Why?
Inhibitor of Apoptosis Proteins
1
2013
39
0.030
Why?
Neoplasm Transplantation
1
2013
165
0.030
Why?
Cause of Death
1
2016
437
0.030
Why?
Chemokine CXCL12
1
2013
18
0.030
Why?
Nicotinamide Mononucleotide
1
2013
2
0.030
Why?
Acrylamides
1
2013
15
0.030
Why?
Enzyme Induction
1
2013
45
0.030
Why?
Receptors, CXCR4
1
2013
36
0.030
Why?
Wnt Proteins
1
2013
98
0.030
Why?
Poly(ADP-ribose) Polymerases
1
2013
32
0.030
Why?
Niacinamide
1
2013
33
0.030
Why?
Transplantation, Heterologous
1
2013
229
0.030
Why?
Poly (ADP-Ribose) Polymerase-1
1
2013
18
0.030
Why?
Coculture Techniques
1
2013
97
0.030
Why?
Sirtuin 1
1
2013
27
0.030
Why?
Amides
1
2013
56
0.030
Why?
CD4 Lymphocyte Count
1
2013
93
0.030
Why?
Nitriles
1
2013
70
0.030
Why?
Wnt Signaling Pathway
1
2013
81
0.030
Why?
NAD
1
2013
53
0.020
Why?
Age Factors
1
2016
1555
0.020
Why?
Endoplasmic Reticulum
1
2013
173
0.020
Why?
Gene Knockdown Techniques
1
2013
200
0.020
Why?
Rabbits
1
2013
331
0.020
Why?
Tumor Suppressor Proteins
1
2013
196
0.020
Why?
Tumor Cells, Cultured
1
2013
456
0.020
Why?
Viral Load
1
2013
231
0.020
Why?
Cell Survival
1
2013
573
0.020
Why?
Genes, Neoplasm
1
2011
24
0.020
Why?
Repressor Proteins
1
2013
347
0.020
Why?
Pharmacogenetics
1
2011
27
0.020
Why?
Enzyme Inhibitors
1
2013
372
0.020
Why?
NF-kappa B
1
2013
469
0.020
Why?
Mice, Transgenic
1
2013
1271
0.020
Why?
Cells, Cultured
1
2013
2152
0.020
Why?
Cell Line
1
2013
2030
0.020
Why?
RNA-Binding Proteins
1
2011
434
0.020
Why?
DNA-Binding Proteins
1
2013
1181
0.020
Why?
Transcription Factors
1
2013
1507
0.020
Why?
Diagnosis, Differential
1
2006
964
0.010
Why?
Usmani's Networks
Click the
Explore
buttons for more information and interactive visualizations!
Concepts (509)
Explore
_
Co-Authors (2)
Explore
_
Similar People (60)
Explore
_
Same Department Expand Description
Explore
_
Physical Neighbors
_